Perspectives

Our perspectives on the problems life sciences cannot afford to get wrong.

Filter

Topics

Every Day Matters: Introducing the New Scimitar

Every day matters when patients are waiting. That conviction opens the new scimitar.com, live now. Scimitar has evolved significantly since its founding in …

2 min

Latest Perspectives

Strategic Innovation 5 min

Kinder, Gentler Isn't Enough: The Real Edge in Next-Gen Oncology Is Moving Downstream in the Pathway
Strategic Innovation 4 min

Community Cancer Care Is the Next Oncology Land Grab-and Most Cell Therapy Companies Aren't Built for It
Commercial Excellence 7 min

The De-Risking Trap: How Oncology Investing Manufactured a Me-Too Pipeline Crisis
AI & Digital 5 min

AI Is Not Ready to Be the Decision-Maker, And Pretending Otherwise Is the Real Risk

Explore how this translates into real client engagements.

Explore Case Studies

From Dealmaking to Strategic Access: The New Partnership Agenda in Life Sciences

Blog 12 min

Strategic Ambition is Not Enough: The Value Realization Imperative for Biopharma

Blog 14 min

The Evolving World of Global Regulatory Affairs: Navigating Change and Embracing Innovation

Blog 4 min

Recent Insights

Every Day Matters: Introducing the New Scimitar

2 min

Kinder, Gentler Isn't Enough: The Real Edge in Next-Gen Oncology Is Moving Downstream in the Pathway

Blog 5 min

Community Cancer Care Is the Next Oncology Land Grab-and Most Cell Therapy Companies Aren't Built for It

Blog 4 min

The De-Risking Trap: How Oncology Investing Manufactured a Me-Too Pipeline Crisis

Blog 7 min

AI Is Not Ready to Be the Decision-Maker, And Pretending Otherwise Is the Real Risk

Blog 5 min

Stop Asking Build vs. Buy: Most Biotechs Don't Have an AI Strategy at All

Blog 5 min

Decision Latency Is a Growth Strategy Problem: Redesigning Portfolio Governance for Speed and Discipline

Blog 14 min

From Dealmaking to Strategic Access: The New Partnership Agenda in Life Sciences

Blog 12 min

1 2 3 4 5 ... 6

Perspectives

Every Day Matters: Introducing the New Scimitar

Latest Perspectives

Kinder, Gentler Isn't Enough: The Real Edge in Next-Gen Oncology Is Moving Downstream in the Pathway

Community Cancer Care Is the Next Oncology Land Grab-and Most Cell Therapy Companies Aren't Built for It

The De-Risking Trap: How Oncology Investing Manufactured a Me-Too Pipeline Crisis

AI Is Not Ready to Be the Decision-Maker, And Pretending Otherwise Is the Real Risk

Explore how this translates into real client engagements.

Operational Excellence

From Dealmaking to Strategic Access: The New Partnership Agenda in Life Sciences

Strategic Ambition is Not Enough: The Value Realization Imperative for Biopharma

The Use of Decentralized Clinical Trials (DCTs)

Challenging Times Require a Disciplined Approach to Process Improvement

Strategic Business Management

The Calendar is the Real Operating System of Leadership (And It's Failing Us)

Escape Meeting Purgatory with Strategic Business Management

Harnessing Structure for Leadership Excellence: A Business Manager's Blueprint

The Evolving World of Global Regulatory Affairs: Navigating Change and Embracing Innovation

Recent Insights

Every Day Matters: Introducing the New Scimitar

Kinder, Gentler Isn't Enough: The Real Edge in Next-Gen Oncology Is Moving Downstream in the Pathway

Community Cancer Care Is the Next Oncology Land Grab-and Most Cell Therapy Companies Aren't Built for It

The De-Risking Trap: How Oncology Investing Manufactured a Me-Too Pipeline Crisis

AI Is Not Ready to Be the Decision-Maker, And Pretending Otherwise Is the Real Risk

Stop Asking Build vs. Buy: Most Biotechs Don't Have an AI Strategy at All

Decision Latency Is a Growth Strategy Problem: Redesigning Portfolio Governance for Speed and Discipline

From Dealmaking to Strategic Access: The New Partnership Agenda in Life Sciences